Raloxifene is a selective estrogen receptor modulator that reduces the risk of vertebral fracture and the incidence of invasive breast cancer in postmenopausal women. The Raloxifene Use for the Heart (RUTH) trial of 10 101 women showed that raloxifene had no overall effect on the incidence of coronary events in women with established coronary heart disease or coronary heart disease risk factors. In this further analysis, we provide detailed results of the effect of raloxifene on coronary outcomes over time and for 22 subgroups (15 predefined, 7 post hoc). The effect of raloxifene was similar across the prespecified subgroups. Therefore, we further analyzed the effect based on a post hoc age subgroup analysis using age categories defined in the Women's Health Initiative randomized trials in an attempt to test the "younger woman hypothesis" for hormone therapy response. The effect of raloxifene on the incidence of coronary events significantly differed by age (interaction Pϭ0.0118). The incidence of coronary events in women Յ60 years of age was significantly lower in those assigned raloxifene (50 events) compared with placebo (84 events; hazard ratio, 0.59; 95% confidence interval, 0.41 to 0.83; Pϭ0.003; absolute risk reduction, 36 per 1000 women treated for 1 year). No difference was found in the incidence of coronary events in women Ն60 and Ͻ70 or Ն70 years of age. Our hypothesis-generating data support the view that the cardiovascular response to hormones and hormone-related drugs may vary, depending on the age of the recipient. See p 922.
Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women
Although current prevention guidelines recommend measurement of standard lipids to assess risk of cardiovascular disease, it has been suggested that alternative lipoprotein measures may improve risk prediction; however, it remains uncertain how well such measures predict cardiovascular disease compared with the standard lipids that are obtained routinely in clinical practice. One method of alternative lipid testing is proton nuclear magnetic resonance spectroscopy. This technique simultaneously quantifies the number (concentration) and size of very low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein particles. Apolipoprotein B 100 is another measure of atherogenic lipoprotein particle number, obtained by immunoassay. By contrast, standard lipid tests quantify the cholesterol or triglyceride content of lipoproteins. In this prospective cohort of 27 673 initially healthy women, nuclear magnetic resonancemeasured lipoproteins were significantly associated with incident cardiovascular disease after adjustment for nonlipid risk factors, with a magnitude of risk comparable but not superior to standard lipids or immunoassay-measured apolipoproteins. Even though nuclear magnetic resonance-measured low-density lipoprotein particle concentration performed well for cardiovascular disease risk prediction in the present study and was similar in risk to apolipoprotein B 100 , neither measurement was better than the total/high-density lipoprotein cholesterol ratio that is readily obtained from a standard lipid panel. Essentially no reclassification improvement was found with the addition of nuclear magnetic resonance-measured low-density lipoprotein particle concentration or apolipoprotein B 100 to a model that already included the total/high-density lipoprotein cholesterol ratio and nonlipid risk factors. These data support current guidelines that recommend the use of standard lipids, in particular the total/high-density lipoprotein cholesterol ratio, which are highly effective and readily available, for routine cardiovascular disease risk assessment. See p 931.
Genetic Variations in Nitric Oxide Synthase 1 Adaptor Protein Are Associated With Sudden Cardiac Death in US White Community-Based Populations
Nearly half of all coronary heart disease deaths are sudden. Family history of sudden cardiac death (SCD) is a powerful risk factor for SCD; however, the genetic factors underlying SCD in the general population are largely unknown. The ECG QT interval is associated with risk of SCD. A previous genome-wide association study reported that allelic variants in Nitric Oxide Synthase 1 Adaptor Protein (NOS1AP), which encodes a ligand of neuronal nitric oxide synthase, are associated with the QT interval in white adults. The present analysis was conducted to validate the association between NOS1AP variants and the QT interval and to further examine the association with SCD in a combined population of 19 295 black and white adults from 2 population-based cohort studies. Among whites, we found that multiple single-nucleotide polymorphisms in NOS1AP were associated with adjusted QT interval in whites (PϽ0.0001), and 2 single-nucleotide polymorphisms were independently associated with SCD. One single-nucleotide polymorphism, with a minor allele frequency of 22%, was associated with a 31% greater risk of SCD for each copy of the variant allele, whereas a neighboring single-nucleotide polymorphism (minor allele frequency 7%) was associated with a 43% lower risk for SCD. No associations between single-nucleotide polymorphisms in NOS1AP and either QT interval or SCD were observed in blacks. Although the genetic effects described here are modest, if replicated in other populations this effort may represent 1 step toward the use of genetic risk markers, along with other risk factors, to help identify patients who warrant our most aggressive SCD preventive strategies. See p 940.
Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras: Results From the US Medicare Program
Although drug-eluting stents have been shown to be cost-effective compared with bare-metal stents for select clinical trial patients, whether these findings apply to the general population is unknown. To address these issues, we used Medicare data to compare the practice and outcomes of coronary revascularization by either percutaneous coronary intervention or coronary artery bypass grafting in the United States between the pre-drug-eluting stent (2001) and post-drug-eluting stent (2004) eras in Ͼ30 000 patients. Over this time period, a shift occurred in the initial form of coronary revascularization from Ϸ67% to Ϸ75% percutaneous coronary intervention. In addition, significant improvements occurred in 2-year outcomes of coronary revascularization, including a 21% reduction in the rate of subsequent myocardial infarction and a 7% reduction in the need for repeat revascularization (with no change in all-cause mortality). From the perspective of the Centers for Medicare and Medicaid Services, these changes were accompanied by a February 24, 2009 significant reduction in the mean cost of cardiovascular care per revascularized patient (by $1680 per patient). Nonetheless, aggregate Medicare spending for coronary revascularization and follow-up care actually increased by Ϸ$450 million because of a parallel increase in the use of revascularization procedures. These findings demonstrate the complex interrelationship between the introduction of drugeluting stents and both the outcomes and costs of coronary revascularization within the US healthcare system. See p 952.
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Weekend Versus Weekday Admission and Mortality After Acute Pulmonary Embolism
Optimal management of acute pulmonary embolism requires medical expertise, diagnostic testing, and therapies that may not be available consistently throughout the entire week. Using data from 186 acute care hospitals in Pennsylvania, we assessed whether associations existed between weekday or weekend admission and mortality and length of hospital stay for patients hospitalized with pulmonary embolism, adjusting for hospital (region, size, and teaching status) and patient factors (race, insurance, severity of illness, and use of thrombolytic therapy). Among 15 531 patient discharges with pulmonary embolism, patients admitted on weekends had a higher unadjusted 30-day mortality rate (11.1% versus 8.8%) than patients admitted on weekdays, with no significant difference in length of hospital stay. Patients admitted on weekends had significantly greater adjusted odds of dying (odds ratio 1.17, 95% confidence interval 1.03 to 1.34) than patients admitted on weekdays. The higher mortality among patients hospitalized on weekends was driven by the increased mortality rate among the most severely ill patients. Further research is needed to investigate the reasons (eg, inadequate professional staffing and medical coverage, suboptimal diagnostic or therapeutic processes of care) for this observed difference in mortality for weekend and weekday admissions to inform future strategies to ensure a consistent approach to management of pulmonary embolism 7 days a week. See p 962.
Cardiac Resynchronization Therapy Reduces the Risk of Hospitalizations in Patients With Advanced Heart Failure: Results From the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Trial
In clinical trials, the true and unbiased assessment of a therapy on hospital admissions is confounded by the competing risk of death and differential follow-up times between treatment groups. To overcome this challenge, we used a novel nonparametric analysis that accounts for multiple hospital admissions, unequal follow-up times between treatment groups, and death as a competing risk in the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Trial. The analysis showed that cardiac resynchronization therapy with or without a defibrillator was associated with marked reductions in all-cause, cardiac, and heart failure hospitalization rates in patients with advanced heart failure. See p 969.
Sympathoexcitation by Oxidative Stress in the Brain Mediates Arterial Pressure Elevation in Obesity-Induced Hypertension
Metabolic syndrome, a highly predisposing condition for cardiovascular disease caused by visceral obesity, requires appropriate management. However, the detailed mechanisms have not been fully elucidated. High salt intake increases blood pressure to a greater degree in patients with metabolic syndrome than in those without it. In the present study, we have demonstrated that sympathoexcitation via oxidative stress in the brain may mediate arterial pressure elevation in obesity-induced hypertension. We have also demonstrated the similar mechanisms in saltsensitive hypertension in a previous study. Therefore, our series of findings suggest that sympathoexcitation via oxidative stress in the brain could be a possible common pathogenic background in metabolic syndrome. This finding is also supported by bodies of clinical studies that suggest that sympathoexcitation and oxidative stress are associated with metabolic syndrome, as well as salt-sensitive and obesity-induced hypertension. An antioxidant with a sympathoinhibitory effect may become a candidate for a new therapeutic strategy to manage the patient with metabolic syndrome. See p 978.
Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation
Randomized data are lacking on the optimal duration of dualantiplatelet therapy after drug-eluting stent implantation and on the risks associated with discontinuation of dual-antiplatelet therapy. Despite the absence of randomized data, the use of dual-antiplatelet therapy beyond 1 year has become commonplace in clinical practice. In the j-Cypher registry, 10 778 Japanese patients treated exclusively by sirolimus-eluting stents were followed up for up to 2 years with prospective data collection on the status of antiplatelet therapy during follow-up. Incidences of definite stent thrombosis were 0.34% at 30 days, 0.54% at 1 year, and 0.77% at 2 years. Thienopyridine use was maintained in 97%, 62%, and 50% of patients at 30 days, 1 year, and 2 years, respectively. The main findings of the present study were that discontinuation of both aspirin and thienopyridine, but not discontinuation of thienopyridine therapy only, was associated with an increased stent thrombosis risk and that no apparent clinical benefit of thienopyridine use could be seen beyond 6 months after sirolimus-eluting stent implantation, according to the 6-month landmark analysis. Given the increased risk of bleeding and huge economic burden associated with prolonged dual-antiplatelet therapy, the optimal duration of dualantiplatelet therapy should be defined by prospective randomized trials evaluating its net clinical benefit after consideration of both ischemic events and bleeding complications. See p 987.
Systemic Arterial Response to Exercise in Patients With Aortic Valve Stenosis
The determinants of the increase in cardiac output with exercise in patients with aortic valve stenosis (AVS) are identical to those in normal individuals and consist of chronotropic competence, increased contractility, adequate ventricular filling, and a reduction in the resistance to forward flow. The last, called vascular hydraulic load, is made up of steady and pulsatile (frequency-dependent) components. Although it is commonly believed that the valvular stenosis itself is mainly responsible for the opposition to forward flow, valvular hemodynamics are, in fact, a function of the arterial vascular hydraulic load. Using high-fidelity catheter-tip manometry and velocimetry during diagnostic cardiac catheterization, we studied the steady (systemic vascular resistance) and pulsatile (arterial compliance and aortic impedance) components of the arterial load in 18 patients with clinically significant (symptomatic) AVS at rest and with supine exercise and compared the response to that of a control group free of cardiovascular disease. We identified increases in systemic vascular resistance and aortic characteristic impedance and diminished total arterial compliance in patients with AVS at rest. With exercise, in contrast to the control subjects, patients with AVS exhibited blunted systemic vasodilation and further decreases in arterial compliance. The stroke output response in control subjects was significantly greater than in AVS and was directly and significantly related to the decrease in systemic vascular resistance and input
